A Phase 2 interventional study of Herceptin and Herceptin in Breast Neoplasms, sponsored by Hoffmann-La Roche. Completed at 75 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 39th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2011, is one of 239 in phase 2, and was the 175th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 19 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 488 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 33rd largest by enrollment of the 170 interventional ones that give a count, is one of 17 that started in 2011, is one of 65 in phase 2, and was the 84th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer. Participants will be randomized to receive either SC Herceptin or IV Herceptin every 3 weeks for Cycles 1 to 4, followed by crossover to the other treatment administration for Cycles 5 to 8. For up to 10 additional cycles (for a total of 18 cycles), participants will receive IV or SC Herceptin every 3 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
Drug: Herceptin · Device: Single-Use Injection Device
Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
Drug: Herceptin · Device: Single-Use Injection Device
Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
Drug: Herceptin
Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
Drug: Herceptin
Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
Also known as: Trastuzumab
Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
Also known as: Trastuzumab
The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
The SID will be used, containing Herceptin 600 mg per 5 mL.
Percentage of Participants by Preferred Method of Drug Administration
The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant. Participants were asked, "All things considered, which method of administration did you prefer?" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported.
Time frame: Week 24
Percentage of HCPs by Most Satisfied Method of Drug Administration
The method of drug administration with which HCPs were most satisfied (IV or SC Herceptin) was assessed via questionnaire with each HCP using the question, "All things considered, with which method of administration were you most satisfied?" at the end of the crossover period (Week 24). The percentage of HCPs who were most satisfied with each method of drug administration was reported.
Time frame: Week 24
Percentage of HCPs by Time Required to Perform Each Method of Drug Administration
The time required to perform each method of drug administration was assessed via questionnaire with each HCP by asking to rate the amount of time it took to administer each method of drug administration (IV or SC Herceptin) at the end of the crossover period (Week 24). Time was rated in the following time block categories: less than (\<) 5 minutes, 6 to 10 minutes, 11 to 15 minutes, 16 to 20 minutes, and greater than (\>) 20 minutes. Responses of "Not Sure" and "Unknown" were also allowed. The percentage of HCPs who rated the amount of time in each of the categories was reported.
Time frame: Week 24
Percentage of Participants With an Event-Free Survival (EFS) Event
EFS events included local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The percentage of participants who had an EFS event at any time on study was reported.
Time frame: From Baseline until time of event; assessed every 6 months (median follow-up of 3 years)
Duration of EFS According to Kaplan-Meier Estimate
EFS was defined as the time from randomization to a local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The median duration of EFS and corresponding 95 percent (%) CI according to Kaplan-Meier estimates were planned to be reported and expressed in months.
Time frame: From Baseline until time of event; assessed every 6 months (median follow-up of 3 years)
3-Year EFS Rate
EFS events included local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The proportion of participants without an EFS event (i.e., the EFS rate) and corresponding 95% CI at 3 years after randomization was reported.
Time frame: Year 3
Percentage of Participants With Responses of "Agree" or "Strongly Agree" on the SC SID Satisfaction Questionnaire
Participants who performed self-administration of SC Herceptin via SID were given an evaluation questionnaire during the continuation period (Weeks 25 to 52) after their first self-administration. Participants responded to 5 statements about their comfort with self-injection, the convenience of the SID, their self-confidence using the SID, their satisfaction with the SID, and whether they would consider using the SID again in the future. Each statement used a 5-item rating scale with responses from "Strongly Disagree" to "Strongly Agree". The percentage of participants with a positive response (either "Agree" or "Strongly Agree") to each questionnaire statement was reported.
Time frame: Immediately following first self-administration of SC Herceptin via SID (once during Weeks 25 to 52)
Percentage of Participants With Anti-Trastuzumab or Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies
Participants in Cohort 1 provided blood samples for immunogenicity testing to assess for anti-drug antibodies (ADAs) to trastuzumab or rHuPH20, a component of the SC Herceptin formulation. The percentage of participants who were trastuzumab ADA-positive and the percentage of participants who were rHuPH20 ADA-positive were each reported.
Time frame: Baseline, pre-dose (0 hours) during Cycle 5 (cycle length of 3 weeks)
| Milestone | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin | Cohort 2: SC (Vial) Then IV Herceptin | Cohort 2: IV Then SC (Vial) Herceptin |
|---|---|---|---|---|
| Started | 122 | 122 | 121 | 118 |
| Completed | 119 | 120 | 119 | 116 |
| Not completed | 3 | 2 | 2 | 2 |
| Milestone | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin | Cohort 2: SC (Vial) Then IV Herceptin | Cohort 2: IV Then SC (Vial) Herceptin |
|---|---|---|---|---|
| Started | 119 | 120 | 119 | 116 |
| Completed | 113 | 116 | 107 | 105 |
| Not completed | 6 | 4 | 12 | 11 |
| Milestone | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin | Cohort 2: SC (Vial) Then IV Herceptin | Cohort 2: IV Then SC (Vial) Herceptin |
|---|---|---|---|---|
| Started | 113 | 116 | 107 | 105 |
| Completed | 109 | 109 | 105 | 102 |
| Not completed | 4 | 7 | 2 | 3 |
| Milestone | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin | Cohort 2: SC (Vial) Then IV Herceptin | Cohort 2: IV Then SC (Vial) Herceptin |
|---|---|---|---|---|
| Started | 124 | 124 | 121 | 119 |
| Completed | 99 | 106 | 104 | 100 |
| Not completed | 25 | 18 | 17 | 19 |
The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant. Participants were asked, "All things considered, which method of administration did you prefer?" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported.
| percentage of participants | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin | Cohort 2: SC (Vial) Then IV Herceptin | Cohort 2: IV Then SC (Vial) Herceptin |
|---|---|---|---|---|
| SC Herceptin | 95.7 | 87.4 | 83.9 | 88.5 |
| IV Herceptin | 4.3 | 9.2 | 13.6 | 11.5 |
| No Preference | 0.0 | 3.4 | 2.5 | 0.0 |
The method of drug administration with which HCPs were most satisfied (IV or SC Herceptin) was assessed via questionnaire with each HCP using the question, "All things considered, with which method of administration were you most satisfied?" at the end of the crossover period (Week 24). The percentage of HCPs who were most satisfied with each method of drug administration was reported.
| percentage of HCPs | All HCPs: SC and IV Herceptin |
|---|---|
| SC Herceptin | 77.0 |
| IV Herceptin | 3.0 |
| No Preference | 20.0 |
The time required to perform each method of drug administration was assessed via questionnaire with each HCP by asking to rate the amount of time it took to administer each method of drug administration (IV or SC Herceptin) at the end of the crossover period (Week 24). Time was rated in the following time block categories: less than (\<) 5 minutes, 6 to 10 minutes, 11 to 15 minutes, 16 to 20 minutes, and greater than (\>) 20 minutes. Responses of "Not Sure" and "Unknown" were also allowed. The percentage of HCPs who rated the amount of time in each of the categories was reported.
| percentage of HCPs | All HCPs: SC and IV Herceptin |
|---|---|
| SC Herceptin, <5 minutes | 44.3 |
| SC Herceptin, 6 to 10 minutes | 46.4 |
| SC Herceptin, 11 to 15 minutes | 3.4 |
| SC Herceptin, 16 to 20 minutes | 0.4 |
| SC Herceptin, >20 minutes | 0.4 |
| SC Herceptin, Not Sure | 0.0 |
| SC Herceptin, Unknown | 5.1 |
| IV Herceptin, <5 minutes | 11.1 |
| IV Herceptin, 6 to 10 minutes | 9.8 |
| IV Herceptin, 11 to 15 minutes | 3.8 |
| IV Herceptin, 16 to 20 minutes | 44.3 |
| IV Herceptin, >20 minutes | 22.1 |
| IV Herceptin, Not Sure | 5.1 |
| IV Herceptin, Unknown | 3.8 |
EFS events included local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The percentage of participants who had an EFS event at any time on study was reported.
| percentage of participants | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin | Cohort 2: SC (Vial) Then IV Herceptin | Cohort 2: IV Then SC (Vial) Herceptin |
|---|---|---|---|---|
| Percentage of Participants With an Event-Free Survival (EFS) Event | 13.7 | 6.7 | 11.9 | 7.1 |
EFS was defined as the time from randomization to a local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The median duration of EFS and corresponding 95 percent (%) CI according to Kaplan-Meier estimates were planned to be reported and expressed in months.
| months | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin | Cohort 2: SC (Vial) Then IV Herceptin | Cohort 2: IV Then SC (Vial) Herceptin |
|---|---|---|---|---|
| Duration of EFS According to Kaplan-Meier Estimate | NA (NA to NA) | NA (42.0 to NA) | NA (NA to NA) | NA (NA to NA) |
EFS events included local, regional, or distant recurrence of the original breast cancer, occurrence of contralateral breast cancer, or death due to any cause. The proportion of participants without an EFS event (i.e., the EFS rate) and corresponding 95% CI at 3 years after randomization was reported.
| proportion of participants | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin | Cohort 2: SC (Vial) Then IV Herceptin | Cohort 2: IV Then SC (Vial) Herceptin |
|---|---|---|---|---|
| 3-Year EFS Rate | 0.849 (0.763 to 0.906) | 0.948 (0.887 to 0.976) | 0.886 (0.811 to 0.932) | 0.937 (0.873 to 0.970) |
Participants who performed self-administration of SC Herceptin via SID were given an evaluation questionnaire during the continuation period (Weeks 25 to 52) after their first self-administration. Participants responded to 5 statements about their comfort with self-injection, the convenience of the SID, their self-confidence using the SID, their satisfaction with the SID, and whether they would consider using the SID again in the future. Each statement used a 5-item rating scale with responses from "Strongly Disagree" to "Strongly Agree". The percentage of participants with a positive response (either "Agree" or "Strongly Agree") to each questionnaire statement was reported.
| percentage of participants | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin |
|---|---|---|
| Comfortable | 94.7 | 86.7 |
| Convenient | 100 | 100 |
| Confident | 100 | 100 |
| Satisfied | 100 | 93.3 |
| Would Use Again | 100 | 93.3 |
Participants in Cohort 1 provided blood samples for immunogenicity testing to assess for anti-drug antibodies (ADAs) to trastuzumab or rHuPH20, a component of the SC Herceptin formulation. The percentage of participants who were trastuzumab ADA-positive and the percentage of participants who were rHuPH20 ADA-positive were each reported.
| percentage of participants | Cohort 1: SC (SID) Then IV Herceptin | Cohort 1: IV Then SC (SID) Herceptin |
|---|---|---|
| Trastuzumab ADA-Positive, Baseline (n=120,121) | 2.5 | 4.1 |
| Trastuzumab ADA-Positive, Cycle 5 (n=114,119) | 0 | 3.4 |
| rHuPH20 ADA-Positive, Baseline (n=120,121) | 5.8 | 7.4 |
| rHuPH20 ADA-Positive, Cycle 5 (n=115,119) | 2.6 | 7.6 |
Collected over During treatment from Cycles 1 to 8 (crossover period) and Cycles 9 to 18 (continuation period); cycle length of 3 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: SC (SID) Herceptin (Crossover) | — | 4/242 (1.7%) | 81/242 (33.5%) |
| Cohort 1: IV Herceptin (Crossover) | — | 2/241 (0.8%) | 55/241 (22.8%) |
| Cohort 1: IV Herceptin (Continuation) | — | 6/226 (2.7%) | 46/226 (20.4%) |
| Cohort 1: SC (SID) Herceptin (Continuation) | — | 1/43 (2.3%) | 7/43 (16.3%) |
| Cohort 1 Overall: SC (SID) and IV Herceptin | — | 12/244 (4.9%) | 130/244 (53.3%) |
| Cohort 2: SC (Vial) Herceptin (Crossover) | — | 0/237 (0%) | 107/237 (45.1%) |
| Cohort 2: IV Herceptin (Crossover) | — | 2/237 (0.8%) | 76/237 (32.1%) |
| Cohort 2: IV Herceptin (Continuation) | — | 0/10 (0%) | 6/10 (60%) |
| Cohort 2: SC (Vial) Herceptin (Continuation) | — | 5/208 (2.4%) | 61/208 (29.3%) |
| Cohort 2 Overall: SC (Vial) and IV Herceptin | — | 7/239 (2.9%) | 154/239 (64.4%) |
| Event | Cohort 1: SC (SID) Herceptin (Crossover) | Cohort 1: IV Herceptin (Crossover) | Cohort 1: IV Herceptin (Continuation) | Cohort 1: SC (SID) Herceptin (Continuation) | Cohort 1 Overall: SC (SID) and IV Herceptin | Cohort 2: SC (Vial) Herceptin (Crossover) | Cohort 2: IV Herceptin (Crossover) | Cohort 2: IV Herceptin (Continuation) | Cohort 2: SC (Vial) Herceptin (Continuation) | Cohort 2 Overall: SC (Vial) and IV Herceptin |
|---|---|---|---|---|---|---|---|---|---|---|
| Cerebral haemangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/242 | 0/241 | 0/226 | 1/43 | 1/244 | 0/237 | 0/237 | 0/10 | 0/208 | 0/239 |
| Wound infectionInfections and infestations | 0/242 | 0/241 | 0/226 | 0/43 | 0/244 | 0/237 | 1/237 | 0/10 | 1/208 | 2/239 |
| Breast reconstructionSurgical and medical procedures | 0/242 | 0/241 | 0/226 | 0/43 | 0/244 | 0/237 | 0/237 | 0/10 | 1/208 | 1/239 |
| Knee arthroplastySurgical and medical procedures | 0/242 | 0/241 | 0/226 | 0/43 | 0/244 | 0/237 | 0/237 | 0/10 | 1/208 | 1/239 |
| MammoplastySurgical and medical procedures | 0/242 | 0/241 | 0/226 | 0/43 | 0/244 | 0/237 | 0/237 | 0/10 | 1/208 | 1/239 |
| Left ventricular dysfunctionCardiac disorders | 0/242 | 0/241 | 0/226 | 0/43 | 0/244 | 0/237 | 0/237 | 0/10 | 1/208 | 1/239 |
| Breast abscessInfections and infestations | 0/242 | 0/241 | 1/226 | 0/43 | 1/244 | 0/237 | 0/237 | 0/10 | 0/208 | 0/239 |
| Postoperative wound infectionInfections and infestations | 0/242 | 0/241 | 1/226 | 0/43 | 1/244 | 0/237 | 0/237 | 0/10 | 0/208 | 0/239 |
| PyelonephritisInfections and infestations | 0/242 | 0/241 | 1/226 | 0/43 | 1/244 | 0/237 | 0/237 | 0/10 | 0/208 | 0/239 |
| Adverse drug reactionGeneral disorders | 0/242 | 0/241 | 1/226 | 0/43 | 1/244 | 0/237 | 0/237 | 0/10 | 0/208 | 0/239 |
| Event | Cohort 1: SC (SID) Herceptin (Crossover) | Cohort 1: IV Herceptin (Crossover) | Cohort 1: IV Herceptin (Continuation) | Cohort 1: SC (SID) Herceptin (Continuation) | Cohort 1 Overall: SC (SID) and IV Herceptin | Cohort 2: SC (Vial) Herceptin (Crossover) | Cohort 2: IV Herceptin (Crossover) | Cohort 2: IV Herceptin (Continuation) | Cohort 2: SC (Vial) Herceptin (Continuation) | Cohort 2 Overall: SC (Vial) and IV Herceptin |
|---|---|---|---|---|---|---|---|---|---|---|
| AstheniaGeneral disorders | 13/242 | 10/241 | 9/226 | 0/43 | 30/244 | 17/237 | 15/237 | 0/10 | 11/208 | 36/239 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/242 | 15/241 | 12/226 | 1/43 | 33/244 | 15/237 | 12/237 | 0/10 | 10/208 | 33/239 |
| HeadacheNervous system disorders | 8/242 | 6/241 | 10/226 | 0/43 | 21/244 | 12/237 | 11/237 | 0/10 | 11/208 | 29/239 |
| Hot flushVascular disorders | 8/242 | 6/241 | 3/226 | 1/43 | 18/244 | 14/237 | 11/237 | 0/10 | 5/208 | 27/239 |
| Injection site painGeneral disorders | 12/242 | 0/241 | 0/226 | 2/43 | 13/244 | 20/237 | 0/237 | 0/10 | 6/208 | 24/239 |
| FatigueGeneral disorders | 8/242 | 10/241 | 7/226 | 0/43 | 23/244 | 11/237 | 8/237 | 1/10 | 5/208 | 21/239 |
| NasopharyngitisInfections and infestations | 5/242 | 7/241 | 5/226 | 1/43 | 16/244 | 6/237 | 3/237 | 1/10 | 6/208 | 13/239 |
| Chest painGeneral disorders | 0/242 | 0/241 | 0/226 | 0/43 | 0/244 | 3/237 | 2/237 | 1/10 | 0/208 | 6/239 |
| Medical device discomfortGeneral disorders | 0/242 | 0/241 | 0/226 | 0/43 | 0/244 | 0/237 | 0/237 | 1/10 | 0/208 | 1/239 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/242 | 0/241 | 0/226 | 0/43 | 0/244 | 2/237 | 3/237 | 1/10 | 4/208 | 10/239 |
Safety Population: All participants who received at least one dose of Herceptin.
| Age, Continuous(years) | Cohort 1 Overall: SC (SID) and IV Herceptin | Cohort 2 Overall: SC (Vial) and IV Herceptin | Total |
|---|---|---|---|
| Mean | 53.3 ± 11.40 | 52.9 ± 10.87 | 53.1 ± 11.13 |
| Sex: Female, Male(Participants) | Cohort 1 Overall: SC (SID) and IV Herceptin | Cohort 2 Overall: SC (Vial) and IV Herceptin | Total |
|---|---|---|---|
| Female | 244 | 239 | 483 |
| Male | 0 | 0 | 0 |
The record gives a start of Oct 2011, a primary completion of May 2013 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab